PolyPid Business Summary

PolyPid Ltd. (PYPD) is a late-stage biopharmaceutical company transitioning from a research-driven entity to a commercial-stage enterprise. The company generates revenue through strategic licensing agreements and anticipated product sales, currently focusing on its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. This platform enables the controlled, localized delivery of active pharmaceutical ingredients over extended periods. PolyPid’s primary business segments include surgical care, led by its Phase 3 candidate D-PLEX100 for the prevention of surgical site infections (SSIs), and an expanding pipeline in oncology (OncoPLEX) and metabolic diseases, including long-acting GLP-1 therapies. As of early 2026, the company is in advanced discussions for a U.S. commercial partnership and has initiated a rolling New Drug Application (NDA) submission with the FDA. Within the localized drug delivery market, PolyPid competes directly with Pacira BioSciences, Heron Therapeutics, and Urogen Pharma, positioning itself as a specialized provider of ultra-long-acting, site-specific therapeutics that minimize systemic toxicity. The company was founded by Dr. Noam Emanuel, the inventor of the PLEX technology and former Chief Scientific Officer. The current leadership team is headed by CEO Dikla Czaczkes Akselbrad, who previously served as the company’s CFO and held executive roles at Compugen Ltd. Supporting her are CFO Jonny Missulawin, a former audit senior at Ernst & Young, and U.S. COO Ori Warshavsky, who brings a background from Aurum Ventures. In late 2025, PolyPid significantly strengthened its governance by appointing Brooke Story, a veteran executive from BD (Becton, Dickinson and Company) and Medtronic, as Chairman of the Board. The medical strategy is led by CMO Dr. Nurit Tweezer-Zaks, formerly of Sanofi and aMOON Venture Capital. Notable board members and early backers include Prof. Yechezkel Barenholz, the co-inventor of Doxil, and major institutional investors such as Aurum Ventures, Rosalind Advisors, and AIGH Capital Management.